Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Receives Average Rating of “Moderate Buy” from Analysts

Shares of Atara Biotherapeutics, Inc. (NASDAQ:ATRA) have earned a consensus rating of “Moderate Buy” from the seven ratings firms that are presently covering the company, Marketbeat reports. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, three have assigned a buy rating and one has issued a strong buy rating on the company. The average 12 month target price among analysts that have updated their coverage on the stock in the last year is $17.75.

Several analysts have commented on the company. Rodman & Renshaw assumed coverage on Atara Biotherapeutics in a report on Friday, December 20th. They issued a “buy” rating and a $25.00 price target for the company. Canaccord Genuity Group lowered their price target on Atara Biotherapeutics from $21.00 to $17.00 and set a “buy” rating for the company in a report on Friday, January 17th. RODMAN&RENSHAW cut Atara Biotherapeutics from a “strong-buy” rating to a “hold” rating in a report on Tuesday, January 21st. TD Cowen upgraded Atara Biotherapeutics to a “strong-buy” rating in a report on Friday, November 29th. Finally, HC Wainwright reiterated a “neutral” rating on shares of Atara Biotherapeutics in a report on Tuesday, January 28th.

Atara Biotherapeutics Price Performance

ATRA opened at $7.34 on Wednesday. The stock has a market capitalization of $42.28 million, a price-to-earnings ratio of -0.28 and a beta of 0.46. The business has a 50-day moving average of $10.52 and a two-hundred day moving average of $9.76. Atara Biotherapeutics has a 12 month low of $5.40 and a 12 month high of $23.44.

Institutional Trading of Atara Biotherapeutics

A number of institutional investors have recently modified their holdings of the company. Point72 Asia Singapore Pte. Ltd. acquired a new position in Atara Biotherapeutics during the 4th quarter worth approximately $48,000. Cubist Systematic Strategies LLC acquired a new position in Atara Biotherapeutics during the 4th quarter worth approximately $169,000. Citadel Advisors LLC lifted its position in Atara Biotherapeutics by 2.6% during the 4th quarter. Citadel Advisors LLC now owns 267,353 shares of the biotechnology company’s stock worth $3,558,000 after acquiring an additional 6,873 shares in the last quarter. Bank of America Corp DE lifted its position in Atara Biotherapeutics by 0.8% during the 4th quarter. Bank of America Corp DE now owns 205,170 shares of the biotechnology company’s stock worth $2,731,000 after acquiring an additional 1,543 shares in the last quarter. Finally, Northern Trust Corp acquired a new position in Atara Biotherapeutics during the 4th quarter worth approximately $149,000. Hedge funds and other institutional investors own 70.90% of the company’s stock.

Atara Biotherapeutics Company Profile

Atara Biotherapeutics, Inc engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma.